6,880 Shares in Illumina, Inc. $ILMN Acquired by Clear Harbor Asset Management LLC

Key Points

• Clear Harbor Asset Management acquired 6,880 Illumina shares worth approximately $1.21 million, while institutional investors collectively own about 89.4% of the company.
• Illumina exceeded quarterly expectations, reporting $1.31 in adjusted earnings per share and $1.16 billion in revenue, up 9.4% year over year; fiscal 2026 EPS guidance remains $5.30–$5.40.
• Investor sentiment is mixed: analysts’ consensus rating is “Hold” with an average price target of $188.40, while substantial recent insider selling—including a roughly $145.6 million sale by director Keith A. Meister—adds caution.

Clear Harbor Asset Management LLC purchased a new position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 6,880 shares of the life sciences company's stock, valued at approximately $1,210,000.

A number of other large investors also recently modified their holdings of ILMN. Empowered Funds LLC raised its holdings in shares of Illumina by 113.7% in the 1st quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company's stock valued at $737,000 after purchasing an additional 4,940 shares in the last quarter. Sivia Capital Partners LLC acquired a new position in shares of Illumina during the second quarter worth $621,000. CW Advisors LLC acquired a new position in shares of Illumina during the second quarter worth $275,000. Marshall Wace LLP grew its stake in shares of Illumina by 49.0% during the second quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company's stock worth $5,691,000 after purchasing an additional 19,618 shares in the last quarter. Finally, Cresset Asset Management LLC increased its holdings in Illumina by 30.9% in the second quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company's stock valued at $706,000 after buying an additional 1,748 shares during the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ILMN has been the topic of a number of analyst reports. Royal Bank Of Canada raised their price target on Illumina from $170.00 to $230.00 and gave the company an "outperform" rating in a research note on Friday, July 31st. Barclays upped their price objective on Illumina from $145.00 to $160.00 and gave the stock an "underweight" rating in a research report on Friday, July 31st. Daiwa Securities Group upgraded Illumina from a "neutral" rating to an "outperform" rating and set a $155.00 price objective on the stock in a report on Thursday, May 14th. Deutsche Bank Aktiengesellschaft lowered Illumina to a "hold" rating in a research report on Wednesday, August 5th. Finally, JPMorgan Chase & Co. boosted their target price on Illumina from $220.00 to $230.00 and gave the stock an "overweight" rating in a research note on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of "Hold" and a consensus target price of $188.40.

Insider Transactions at Illumina

In related news, insider Scott M. Davies sold 615 shares of the company's stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $200.00, for a total value of $123,000.00. Following the completion of the sale, the insider directly owned 20,338 shares of the company's stock, valued at $4,067,600. This represents a 2.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 783 shares of the firm's stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $162.59, for a total value of $127,307.97. Following the transaction, the senior vice president owned 21,259 shares in the company, valued at $3,456,500.81. This represents a 3.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 2,095,958 shares of company stock worth $401,720,974 over the last three months. 2.90% of the stock is currently owned by company insiders.

Key Headlines Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina’s latest quarterly results exceeded expectations, with earnings of $1.31 per share versus the $1.23 consensus estimate and revenue of $1.16 billion versus expectations of $1.13 billion. Revenue increased 9.4% year over year, while fiscal 2026 EPS guidance remains $5.30-$5.40. Illumina stock information
• Positive Sentiment: Several institutional investors increased their positions, including Marshall Wace, Cresset Asset Management and Empowered Funds. Hedge funds and other institutions collectively own approximately 89.4% of ILMN shares, indicating strong professional-investor participation.
• Neutral Sentiment: Analyst opinions remain mixed. Zacks Research upgraded the stock to “strong buy,” and Leerink Partners raised its target to $210, while Deutsche Bank downgraded the shares to “hold.” The overall consensus rating is “hold,” with an average target of $188.40—below recent trading levels. Analyst coverage of Illumina
• Negative Sentiment: Director Keith A. Meister sold 679,574 Illumina shares from August 19 through August 21 for approximately $145.6 million. The transactions reduced his ownership by roughly one-third, although he still holds about 1.41 million shares. The size and timing of the sales may raise concerns about insider conviction, even though the filings do not establish the reason for the transactions. SEC insider ownership filing
• Negative Sentiment: SVP Christensen Jakob Wedel also sold 1,033 shares under a pre-arranged Rule 10b5-1 trading plan. The smaller, planned transaction is less concerning than Meister’s sales but adds to the recent pattern of insider selling. Illumina insider trading alert

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $219.40 on Friday. The company's fifty day moving average price is $188.01 and its 200 day moving average price is $152.44. Illumina, Inc. has a 12 month low of $88.00 and a 12 month high of $220.43. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The firm has a market capitalization of $33.13 billion, a P/E ratio of 40.93, a P/E/G ratio of 3.09 and a beta of 1.45.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating analysts' consensus estimates of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The firm had revenue of $1.16 billion during the quarter, compared to analysts' expectations of $1.13 billion. During the same period in the previous year, the company earned $1.19 earnings per share. Illumina's quarterly revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, sell-side analysts predict that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source